Oxytocin regulatory status
Current status of Oxytocin in the United States: FDA approved. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of Oxytocin?
Regulatory: FDA approvedWADA: Not WADA prohibitedVerified: Verified Sep 23, 2026
- FDA and compounding
- Oxytocin injection is FDA approved (Pitocin and generics) for obstetric indications. Because oxytocin is the active ingredient of an approved drug, 503A pharmacies may compound it in other dosage forms such as nasal sprays or lozenges for individual prescriptions; these compounded products are not FDA approved, have no approved indication, and have not been shown to achieve meaningful brain levels. Oxytocin is a 9 amino acid peptide and was not among the products transitioned to biologic status in March 2020, so it remains eligible for compounding. No intranasal oxytocin product is FDA approved in the United States.
- WADA
- Not WADA prohibited
- Access path
- Prescription injectable used in hospitals and clinics for labor and postpartum care.
- Prescription filled by a 503A compounding pharmacy as a nasal spray or lozenge (not an FDA approved formulation).
- Telehealth and peptide clinics prescribing compounded intranasal oxytocin off-label.
Full Oxytocin page: evidence, dosing in the literature, and sources
How has the status of Oxytocin changed over time?
No dated regulatory event has been recorded for Oxytocin. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Oxytocin and the source of each dated event.
- [1]FDA prescribing information for Pitocin (oxytocin injection), via DailyMedFDA, 2026
- [2]FDA: Compounding and the FDA, questions and answersFDA, 2026
- [3]WADA Prohibited ListWADA, 2026